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Proteomic and Metabolomic Approaches to
Diagnose Diabetes and Pre-Diabetes
More than 5 million adults in the United States
have undiagnosed type 2 diabetes mellitus, and
another 38 million with pre-diabetes are at
increased risk for developing diabetes. The lack of a
simple and reliable way to detect diabetes and pre-
diabetes has hindered identification of these indi-
viduals and provision of effective therapies. The
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) encourages the applica-
tion of proteomic and other novel technologies to
develop new diagnostic tests and/or to identify new
biomarkers for the diagnosis of pre-diabetes and/or
diabetes that do not require fasting or glucose
administration.
Diabetes is a metabolic disease characterized by
hyperglycemia that in 2002 affected nearly 9% of
U.S. adults. More than 90% of the people with dia-
betes have type 2 diabetes. The symptoms of type 2
diabetes develop gradually. Some people have no
symptoms until after they develop complications,
which could have been prevented or delayed with
early diagnosis and effective treatment. Addi-
tionally, 38 million U.S. adults aged 40–74 have
pre-diabetes. Pre-diabetes is defined as impaired
fasting glucose or impaired glucose tolerance
(http://www.diabetes.org/diabetes-prevention/
pre-diabetes.jsp). These individuals have glucose
levels above normal but below the level needed for
diagnosis of diabetes. They are at increased risk of
cardiovascular disease compared to those with nor-
mal glucose tolerance, and are at substantial risk for
developing diabetes. 
Clinical trials have demonstrated effective
interventions for preventing or delaying complica-
tions in those with diabetes and for preventing or
delaying onset of diabetes in those with pre-dia-
betes. However, millions of Americans are not
receiving effective therapy, in part due to the limi-
tations of current methods of diagnosing diabetes
and pre-diabetes. The oral glucose tolerance test
(OGTT)—the gold standard for diagnosis of dia-
betes and pre-diabetes—is inconvenient, requires
fasting, and is not highly reproducible. The fasting
blood glucose is less burdensome but much less
sensitive, particularly in older Americans, who have
the highest prevalence of diabetes and pre-diabetes.
The quantitation of hemoglobin A1c (a glycated
form of hemoglobin) from blood has been widely
used as a test for assessing the adequacy of glycemic
control and risk of complications in diabetic
patients, but this test is not sufficiently sensitive to
detect the range of glucose values typically seen in
pre-diabetes or new-onset type 2 diabetes.
Furthermore, there are many variants of hemoglo-
bin present in blood, particularly in minority popu-
lations that are disproportionately affected by
diabetes, and this adds additional uncertainty to
the use of this test.
A simplified, less burdensome approach to the
diagnosis of diabetes and pre-diabetes would facili-
tate increased recognition and improved care of
these conditions. Many proteins and other blood
components may be modified in individuals with
elevated blood glucose. Identification of these mol-
ecules or of identifiable correlates of hyperglycemia
would facilitate development of potential new labo-
ratory tests for diagnosis of diabetes and pre-dia-
betes. With this initiative, we are encouraging
scientists with expertise in proteomics and
metabolomics to develop new tests to detect pre-
diabetes and diabetes that correlate with the results
of the OGTT but do not require fasting or admin-
istration of glucose. 
Proteomic and metabolomic approaches have
been successfully used for studying complex biolog-
ical problems and for the identification of disease
markers. Recent developments indicate that these
technologies could be used or appropriately modi-
fied for developing new methods to diagnose dia-
betes and pre-diabetes. For example, mass
spectrometry has been successfully used for the
identification and quantitation of large numbers of
proteins from plasma. Similar studies were per-
formed for quantifying large numbers of metabo-
lites. In some cases, fractionation prior to the mass
spectrometric analysis was shown to be very effec-
tive for increasing the number of proteins and
metabolites that could be identified, and further
development in fractionation methodologies could
perhaps be the key for the identification of novel
biomarkers. The use of isotopically labeled reagents
recently made many proteomic methodologies
usable for quantitative studies, and further develop-
ment of these reagents might also lead to a more
comprehensive analysis of the sera proteome and
possible identification of novel biomarkers.
This initiative solicits the application of pro-
teomic and metabolomic technologies for the
development of novel methodologies and/or the id-
entification of new biomarkers for the diagnosis of
pre-diabetes and type 2 diabetes that do not
require fasting or glucose administration. To facili-
tate this effort, plasma from well-characterized
individuals of diverse racial and ethnic back-
grounds with normal glucose tolerance, impaired
glucose tolerance, and type 2 diabetes will be made
available to investigators for validation of potential
new diagnostic tests. 
The novel diagnostic test could ultimately be
used in place of the OGTT, if adequately validated,
or for the identification of high-risk individuals
who should undergo testing for diabetes and pre-
diabetes using a more functional assay such as the
OGTT. Focused deployment of the OGTT in
appropriately selected individuals would reduce
costs, limit burden, and improve the yield of diag-
nostic testing for diabetes and pre-diabetes. 
This special-emphasis program announcement
(PAR) will use the NIH Exploratory/Development
Research Grant (R21) combined with the Explor-
atory/Development Research Grant Phase 2 (R33).
The R33 is an NIH grant mechanism that provides
a second phase for the support of innovative
exploratory and developmental research initiated
under the R21 mechanism. The transition of the
R21 to the R33 phase will be expedited and is
dependent on completion of negotiated milestones.
As an applicant, you will be solely responsible for
planning, directing, and executing the proposed
project. This PAR is a one-time solicitation. Future
unsolicited, competing-continuation applications
based on this project will have to be submitted
using a standard R01 or R21 mechanism, will com-
pete with all investigator-initiated applications, and
will be reviewed according to the customary peer-
review procedures. 
To be considered for the transition to the R33
phase, the applicant must show that he/she has
identified differences between the pre-diabetes,
diabetes, and normal patient samples provided by
the NIDDK for the R21 phase (i.e., applicant
must have identified at least one potential bio-
marker for pre-diabetes and/or diabetes). These
differences should be determined in a reproducible
and quantitative way and with a throughput that
shows promise for translation to a clinical setting.
In addition, the investigator can include in the
proposal the use of samples from other clinical
studies for optimizing or further validating the
methodology.
For the purpose of assessing research progress
and facilitating interaction between the 4–5 funded
principal investigators, a workshop will be held in
May/June 2006 in Bethesda, Maryland. All funded
principal investigators are required to attend, and
collaborators are encouraged to participate. Funds
for attending this meeting should be included in the
budget proposal.
This PAR uses just-in-time concepts. It also
uses the modular as well as the nonmodular budget-
ing formats (see http://grants.nih.gov/grants/
funding/modular/modular.htm). Specifically, if you
are submitting an application with direct costs in
each year of $250,000 or less, use the modular for-
mat. Otherwise, follow the instructions for nonmod-
ular research grant applications. This program does
not require cost sharing as defined in the current
NIH Grants Policy Statement at http://odoerdb2.
od.nih.gov/gmac/nihgps_2003/index.htm. 
The NIDDK intends to commit approximately
$1 million in direct costs for ﬁscal year 2005 to fund
4–5 new grants in response to this PAR. An appli-
cant may request a project period of 2 years for the
R21 phase and 3 years for the R33 phase. The R21
phase may not exceed $250,000 in direct costs per
year. The R21 budgets can exceed this cap to accom-
modate facilities and administrative costs to subcon-
tracts to the project, in which case a nonmodular
budget format must be used. The R33 application
has a budgetary limit of $500,000 in direct costs for
each year. Awards pursuant to this PAR are contin-
gent upon the availability of funds and the receipt of
a sufﬁcient number of meritorious applications. 
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The DUNS number can be obtained by calling 1-866-
705-5711 or through the website at http://www.
dunandbradstreet.com/. The PHS 398 document is
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format. For fur-
ther assistance, contact GrantsInfo, 301-435-0714, e-
mail: GrantsInfo@nih.gov. 
Letters of intent are due 18 June 2004, with
applications due 20 July 2004. The anticipated
award date is 1 April 2005. Applications that are not
funded in the competition described in this PAR
may be resubmitted as new investigator-initiated
applications using the standard receipt dates for new
applications described in the instructions to the PHS
398 application. For more information on this PAR,
see http://grants.nih.gov/grants/guide/pa-files/
Contact: Direct questions about scientific and
research issues to Salvatore Sechi, Division of
Diabetes, Endocrinology, and Metabolic Diseases,
NIDDK, 6707 Democracy Blvd, Rm 611,
Bethesda, MD 20892-5460 USA, 301-594-8814,
fax: 301-480-2688, e-mail: ss24q@nih.gov; direct
questions about peer review issues to Francisco O.
Calvo, Division of Extramural Activities, NIDDK,
6707 Democracy Blvd, Rm 752, Bethesda, MD
20892-5452 USA, 301-594-8897, fax: 301-480-
3505, e-mail: fc15y@nih.gov; direct questions
about financial and grants management matters to
Kathleen Shino, Grants Management Branch,
NIDDK, 6707 Democracy Blvd, Rm 708,
Bethesda, MD 20892-5460 USA, 301-594-8869,
fax: 301-594-9523, e-mail: ks48e@nih.gov.
Reference: PA No. PAR-04-076
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PAR-04-076.html.In Vivo Cellular and Molecular Imaging Centers
(ICMICs)
The Cancer Imaging Program, a program of the
Division of Cancer Diagnosis and Treatment of the
National Cancer Institute (NCI), invites applica-
tions for new or competing P50 research center
grants for In Vivo Cellular and Molecular Imaging
Centers (ICMICs). This initiative is designed to
capitalize on the extraordinary opportunity for mol-
ecular imaging to have an impact on the diagnosis
and treatment of cancer patients noninvasively and
quantitatively. Molecular imaging technologies can
provide valuable laboratory tools for the interroga-
tion of biological pathways relevant to cancer, as
well as to provide imaging agents and technologies
that will be directly utilized in the clinic. 
The 5-year P50 ICMIC grants described in this
program announcement (PAR) are designed to
bring together interdisciplinary scientific teams to
lead the nation in cutting-edge cancer molecular
imaging research with clinical relevance, provide
unique core facilities to support oncology imaging
research, provide flexibility to respond to exciting
pilot research opportunities, and provide interdisci-
plinary career development opportunities for inves-
tigators new to the field of molecular cancer
imaging. The P50 mechanism will promote coordi-
nation, interrelationships, and scientific synergy
among the research components and resources,
leading to a highly integrated imaging center. 
The ﬁeld of molecular imaging has made signif-
icant advances in recent years. The formation of
multidisciplinary research teams has stimulated and
streamlined cancer imaging research from inception
to use in patient care. The P50 ICMIC structure
allows mechanistic flexibility for each institution to
capitalize on its own unique scientiﬁc strengths, and
to define the structure and research objectives that
create the most synergistic and creative scientific
interactions. In general, an ICMIC will provide
researchers with the following critical resources, as
described below:
The ICMICs will provide an organizational
structure specifically designed to facilitate multidis-
ciplinary interactions among investigators focused
on the ultimate goal of discovering, developing, and
translating molecular imaging technologies that will
have eventual impact in the clinic. This structure
will provide researchers with access to a concen-
trated pool of expertise in a wide range of disci-
plines. The structure of the ICMIC will be designed
to provide investigators with the means to conduct
multidisciplinary research in a highly collaborative
atmosphere; investigators will also have consistent
access to expertise, with minimal wasted time and
effort. Personnel may be scientists from a variety of
fields including, but not limited to, imaging sci-
ences, chemistry, radiopharmaceutical chemistry,
cell and molecular biology, pathology, pharmacol-
ogy, computational sciences, and biomedical engi-
neering. Other specialists in fields such as MRI
physics, immunology, or neuroscience, for example,
may also be involved. Most importantly, ICMIC
personnel must demonstrate an eagerness to collab-
orate outside of their own disciplines. The nature of
these interactions will be determined by the appli-
cants, and emphasis will be placed on establishing
creative, productive, and synergistic interactions
with eventual clinical impact.
The ICMICs will provide funding for a mini-
mum of three research components. Research com-
ponents will apply multidisciplinary approaches to
molecular imaging. Individual research projects
will be structured in order to maximize appropriate
scientific interaction between the projects and
coordinated utilization of the center’s specialized
resources as described below. Each research compo-
nent will be similar in size and scope to a typical
R01 or subproject of a P01, and will be expected to
meet the same standards of preliminary data in
support of the hypotheses.
The ICMICs will provide specialized resource
facilities and services. A barrier to productive scien-
tific interaction is the lack of available facilities for
cross-disciplinary experiments. Demands on equip-
ment, resources, and reagents in every scientiﬁc area
are extremely high, and these demands prohibit
ready access for investigators interested in expand-
ing their studies into new areas of research. The
establishment of specialized resources dedicated to
ICMIC-related research will provide this access.
The specialized resource(s) will be determined by
the requirements of the institution, the defined sci-
entific goals of the research components of the
ICMIC, and budgetary limits. Prioritization of the
research projects supported through ICMIC special-
ized resources will be an essential function of the
ICMIC’s leadership, and the mechanism to be
employed for prioritization must be delineated by
the applicants. Resource facilities may be utilized by
active members of the ICMIC and will also be avail-
able to investigators supported through develop-
mental funds.
ICMICs will provide developmental funds for
feasibility testing of new projects. A high priority of
each ICMIC will be the identification and support
of pilot projects that identify and stimulate interdis-
ciplinary projects that will take full advantage of
emerging research opportunities. The selection of
projects will be through a review process established
by the ICMIC’s leadership. 
The portfolio of ongoing projects in any given
program is expected to be extremely dynamic. This
fund is not to be used to support traditional, ongo-
ing projects that could readily be supported through
R01s. It is not appropriate to use for projects that
utilize single areas of expertise or to support the
continuation of previously funded research projects,
and developmental projects may not be supported
for more than 2 years. Necessary equipment should
be provided through the appropriate specialized
resource. These projects are to be monitored closely
by the ICMIC leadership. Investigators working on
projects supported through the development fund
must understand that they will be expected to com-
pete for independent R01 funding when the pro-
jects become sufficiently mature. Alternately, if it
becomes obvious that the project will not provide
the expected results, a plan should be in place for
terminating a development project.
ICMICs will provide career development
opportunities for new and established investigators.
Current graduate programs are generally focused on
single disciplines and may be inadequate to train the
needed cadre of interdisciplinary imaging scientists.
The ICMICs will provide support for a limited
number of pre- and postdoctoral trainees in a pro-
gram to be deﬁned by the applicants. Career devel-
opment opportunities through the ICMIC will be
expected to be highly cross-disciplinary.
This PAR will use the NIH P50 Specialized
Centers Grant mechanism. As an applicant, you will
be solely responsible for planning, directing, and
executing the proposed project. The total project
period for a P50 application submitted in response
to this PAR may not exceed 5 years. The total costs
requested for a new or competing renewal P50
ICMIC application may not exceed a maximum of
$2 million per year. The NCI anticipates awarding
2 new or competing P50 ICMICs each year.
This PAR uses just-in-time concepts. It also
uses the nonmodular budgeting formats. Follow the
instructions for nonmodular budget research grant
applications. This program does not require cost
sharing as deﬁned in the current NIH Grants Policy
Statement at http://grants.nih.gov/grants/policy/
nihgps_2003/NIHGPS_Part2.htm.
ICMIC investigators will be expected to partic-
ipate in ICMIC workshops and investigator meet-
ings as necessary to share results with other
ICMICs, share materials, assess progress, identify
new research opportunities, and establish interac-
tions and research priorities and collaborations.
Travel funds for the principal investigator and
selected ICMIC investigators and collaborators may
be budgeted for this purpose.
For those projects that involve clinical trials,
investigators must include a general description of
the data and safety monitoring plan (for details, see 
http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-00-038.html) in the application. All
clinical trials supported or performed by NIH
require some form of monitoring. The method and
degree of monitoring should be commensurate with
the degree of risk involved in participation and the
size and complexity of the clinical trial. Monitoring
exists on a continuum from monitoring by the prin-
cipal investigator/project manager or NIH program
staff to a data and safety monitoring board. These
monitoring activities are distinct from the require-
ment for study review and approval by an institu-
tional review board. For further details about the
policy of the data and safety monitoring of clinical
trials, see http://deainfo.nci.nih.gov/grantspolicies/
datasafety.htm.
All investigator-initiated applications with
direct costs greater than $500,000 in any single year
will be expected to address data sharing (see 
http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-03-032.html) in their application. 
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The DUNS number can be obtained by calling 1-
866-705-5711 or through the website at http://
www.dunandbradstreet.com/. The PHS 398 docu-
ment is available at http://grants.nih.gov/grants/
funding/phs398/phs398.html in an interactive for-
mat. For further assistance, contact GrantsInfo, 301-
435-0714, e-mail: GrantsInfo@nih.gov. 
Letters of intent are due 22 June 2004 or 21
June 2005, with applications due 22 July 2004 or 21
July 2005. For more information, see http://grants.
nih.gov/grants/guide/pa-ﬁles/PAR-04-069.html. 
Contact: Direct questions about scientific and
research issues to Anne E. Menkens, Cancer
Imaging Program, NCI, 6130 Executive Blvd, EPN
Rm 6068, Bethesda, MD 20892-8329 USA, 301-
496-9531, fax: 301-480-3507, e-mail: am187k@
nih.gov; direct questions about peer review issues
to the Referral Officer, Division of Extramural
Activities, NCI, 6116 Executive Blvd, Rm 8041,
MSC 8329, Bethesda, MD 20892-8329 USA,
301-496-3428, fax: 301-402-0275, e-mail: ncire-
fof@dea.nci.nih.gov; direct questions about finan-
cial and grants management matters to Kathryn
Dunn, Grants Management Specialist, Grants
Administration Branch, NCI, 6120 Executive
Blvd, EPS Rm 243, Bethesda, MD 20892 USA,
301-846-6829, fax: 301-846-5720, e-mail:
dunnkath@mail.nih.gov. Reference: PA No.
PAR-04-069
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NIEHS Laboratory of Molecular Genetics
Immunoglobulin Hypermutation and the
Memory B cell Response  (HNV03-30)
A postdoctoral position is available in the
Molecular Immunology and Hypermutation
Group, in the Laboratory of Molecular
Genetics, to work on the mechanism of
somatic mutagenesis of immunoglobulin
genes, and the dynamics of the memory B
cell response. Candidates should have experi-
ence in both, tissue culture and molecular
genetics, including the construction of tar-
geting vectors to make knockout and/or
transgenic mice, southern and northern
hybridization, PCR, DNA sequencing, and
standard cloning procedures. Candidates
should also have a strong background in
immunology or in DNA repair (with some
immunology). In general, this laboratory is
concerned with the mechanistic aspects of
the hypermutation reaction, the signal trans-
duction pathways that lead to the formation
of memory B cells, and the selection mecha-
nism by which high affinity variants are
recruited into the memory compartment.
For more information, see the references
listed below. In addition, this laboratory will
also explore the links between immunoglob-
ulin hypermutation and generalized mecha-
nisms of DNA repair and/or replication that
can result in mutagenesis.
My laboratory group is in the National
Institute of Environmental Sciences in the
Research Triangle Park, North Carolina on
the shore of a small lake. The NIEHS
resides in an extraordinarily attractive area
with ready access to mountains, the
seashore, and a myriad of natural habitats
including some that are unique. Our labs
are spacious and well equipped, and almost
any imaginable specialty is practiced here or
nearby. Postdoctoral stipends are at least
$37,200 per year (based on experience) plus
health insurance. Living costs are generally
moderate.
Applicants must not possess more than five
years of post doctorial experience. To apply,
submit a cover letter, curriculum vitae, bibli-
ography, and names of three references to
the hiring scientist at the corresponding lab-
oratory and mail drop in care of NIEHS, PO
Box 12233, Research Triangle Park, NC
27709 USA. The cover letter should include
the position title and HNV number. The
NIEHS is an equal opportunity employer.
Contact: Dr. Marilyn Diaz, Laboratory
of Molecular Genetics, MD D3-01, 
919-541-4740, fax: 919-541-7593, e-mail:
diaz@niehs.nih.govCareer Opportunities
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NIEHS
The Role of Estrogen Receptors in the
Lung (HNV03-32)
A postdoctoral position is available at
NIH/NIEHS to study the role of estrogen
receptors in the lung. The focus of the studies
will be two-fold: 1) Examining the physiologi-
cal effects of estrogen receptors in the lung
using various disease models which are already
established in the lab. These include, animal
models of estrogen receptor knockout mice,
allergic airway disease, models of lung inﬂam-
mation and fibrosis and infectious lung dis-
eases. 2) Examining gene regulation by estrogen
receptors in these models using state-of-the-art
techniques including DNA microarray.
Applicants should possess a Ph.D. degree in
Molecular Biology, Cell Biology, Biochemistry,
Pharmacology, Toxicology, or a related ﬁeld, and
have less than ﬁve years of relevant postdoctoral
experience. Experience in estrogen receptors and
gene regulation is preferred but not required.
Salary will be commensurate with experience.
Applicants must not possess more than five
years of post doctorial experience. To apply,
submit a cover letter, curriculum vitae, bibliog-
raphy, and names of three references to the hir-
ing scientist at the corresponding laboratory
and mail drop in care of NIEHS, PO Box
12233, Research Triangle Park, NC 27709
USA. The cover letter should include the posi-
tion title and HNV number. The NIEHS is an
equal opportunity employer.
Contact: Darryl C. Zeldin, M.D., Laboratory
of Pulmonary Pathobiology, MD D2-01,
919-541-1169, fax: 919-541-4133, e-mail:
zeldin@niehs.nih.gov
Laboratory of Pulmonary
PathobiologyA 380 VOLUME 112 | NUMBER 6 | May 2004 • Environmental Health Perspectives
2004
June
1–3 June, Tue–Thu. U.S. EPA Science Forum 2004:
Healthy Communities and Ecosystems. Washington,
DC. Information: Alina Martin of Science Applications
International Corporation (SAIC), 703-318-4678, e-mail:
tcs-events@saic.com, Internet: http://www.epa.gov/ord/
scienceforum/
1–4 June, Tue–Fri. International Conference for
Renewable Energies. Bonn, Germany. Information:
Secretariat of the International Conference for
Renewable Energies, Bonn 2004, Postfach 5180, 65726
Eschborn, Germany, +49 6196 794404, fax: +49 6196
794405, e-mail: info@renewables2004.de, Internet:
http://www.renewables2004.de/
3–5 June, Thu–Sat. 13th International Symposium on
HIV & Emerging Infectious Diseases. Toulon, France.
Information: Patricia Lhote, Overcome, 3 - 5 Boulevard
Paul Emile Victor, F-92523 Neuilly-Sur-Seine Cedex,
France, +33-1-41-92-01-20, fax: +33-1-46-41-05-21, 
e-mail: avps@club-internet.fr, Internet: http://www.avps.org/
2003/hiv.htm
6–11 June, Sun–Fri. Environmental Endocrine Disruptors.
New London, New Hampshire. Information: Gordon
Research Conferences, PO Box 984, West Kingston, RI
02892-0984 USA, 401-783-4011, fax: 401-783-7644, 
e-mail: grc@grc.org, Internet: http://www.grc.uri.edu
12–16 June, Sat–Wed. IUBMB/ASBMB 2004: A
Molecular Exploration of the Cell. Boston, Massachusetts.
Information: ASBMB Meetings Office, 9650 Rockville
Pike, Bethesda, MD 20814-3996 USA, 301-634-7145, fax:
301-634-7126, e-mail: kgull@asbmb.faseb.org, Internet:
http://www.asbmb.org/asbmb/site.nsf/main/meetings
13–15 June, Sun–Tue. PCB Workshop. Champaign/
Urbana, Illinois. Information: Buzz Swett, The University
of Iowa, 100 Oakdale Campus #219 IREH, Iowa City, IA
52242-5000 USA, 319-335-4554, e-mail: swett@
uiuc.edu, Internet: http://www-apps.niehs.nih.gov/sbrp/
Conf2000/Conf.cfm
16–19 June, Wed–Sat. Advances in Neuroblastoma
Research 2004. Genoa, Italy. Information: ANR 2004
c/o Italian Neuroblastoma Association, Via Merano, 4/2,
Genoa 16154 Italy, +39 010 6018938, fax: +39 010
6018961, e-mail: anr2004@neuroblastoma.org, Internet:
http://www.anr2004.org
20–25 June, Sun–Fri. Cellular & Molecular Fungal
Biology. Plymouth, New Hampshire. Information:
Gordon Research Conferences, PO Box 984, West
Kingston, RI 02892-0984 USA, 401-783-4011, fax: 401-
783-7644, e-mail: grc@grcmail.grc.uri.edu, Internet:
http://www.grc.uri.edu
20–25 June, Sun–Fri. Environmental Bioinorganic
Chemistry. Lewiston, Maine. Information: Gordon
Research Conferences, PO Box 984, West Kingston, RI
02892-0984 USA, 401-783-4011, fax: 401-783-7644, 
e-mail: grc@grc.org, Internet: http://www.grc.uri.edu
22–25 June, Tue–Fri. Air & Waste Management
Association's 97th Annual Conference & Exhibition.
Indianapolis, Indiana. Information: Air & Waste
Management Association, One Gateway Center, 3rd Floor,
420 Fort Duquesne Boulevard, Pittsburgh, PA 15222-
1435 USA, 412-232-3444, fax: 412-232-3450, e-mail:
aklaus@awma.org, Internet: http://www.awma.org/
ACE2004/
23–25 June, Wed–Fri. Fourth Ministerial Conference on
Environment and Health: The Future of Our Children.
Budapest, Hungary. Information: World Health
Organization Regional Ofﬁce for Europe, Scherﬁgsvej 8,
DK-2100, Copenhagen Ø, Denmark, +45 39 17 17 17,
fax: +45 39 17 18 18, e-mail: postmaster@who.dk,
Internet: http://www.who.dk/whd/20030307_20
27 June–2 July, Sun–Fri. Environmental Sciences: Water.
Plymouth, New Hampshire. Information: Gordon
Research Conferences, PO Box 984, West Kingston, RI
02892-0984 USA, 401-783-4011, fax: 401-783-7644, 
e-mail: grc@grc.org, Internet: http://www.grc.uri.edu
30 June–2 July, Wed–Fri. Twelfth International
Conference on Modelling, Monitoring and Management
of Air Pollution. Rhodes, Greece. Information: Stacey
Hobbs, Senior Conference Co-ordinator, Air Pollution
2004, Wessex Institute of Technology, Ashurst Lodge,
Ashurst Southampton, SO40 7AA UK, 44 (0) 238 029
3223, fax: 44 (0) 238 029 2853, e-mail: shobbs@wessex.
ac.uk, Internet: http://www.wessex.ac.uk/conferences/
2004/air04/index.html
July
3–6 July, Sat–Tue. 18th Meeting of the European
Association of Cancer Research. Innsbruck, Austria.
Information: FECS - the Federation of European Cancer
Societies, Avenue E. Mounier 83, B-1200 Brussels, +32-2-
775-02-01, fax: +32-2-775-02-00, e-mail: info@fecs.be,
Internet: http://www.fecs.be
4–8 July, Sun–Thu. Interact 2004. Gold Coast,
Queensland, Australia. Information: Jon Gordon, Carillon
Conference Management Pty Ltd, PO Box 177, RED
HILL QLD 4059, Australia, +61 733682644, fax: +61
733693731, e-mail: interact2004@ccm.com.au, Internet:
http://www.interact2004.com
4–9 July, Sun–Fri. Metabolic Basis of Ecology. Lewiston,
Maine. Information: Gordon Research Conferences, PO
Box 984, West Kingston, RI 02892-0984 USA, 401-783-
4011, fax: 401-783-7644, e-mail: grc@grcmail.grc.uri.edu,
Internet: http://www.grc.uri.edu
5–7 July, Mon–Wed. Ecological Relevance of Chemically
Induced Endocrine Disruption in Wildlife. Exeter,
United Kingdom. Information: School of Biological and
Chemical Sciences, University of Exeter, Prince of Wales
Road, Exeter, EX4 4PS United Kingdom, +44(0)1392-
264450, fax: +44(0)1392-263700, Internet: http://
www.ex.ac.uk/emfb/workshop/
8–10 July, Thu–Sat. Linking Toxicology to Epidemiology:
Biomarkers and New Technologies. Porvoo, Finland.
Information: ICT X Satellite Meeting Secretariat, Finnish
Institute of Occupational Health, Satu-Marja Snellman,
+358 9 4747 2148, fax: +358 9 4747 2110, e-mail:
sasn@ttl.ﬁ, Internet: http://www.ttl.ﬁ/ictxmolepi
11–15 July, Sun–Thu. 10th International Congress of
Toxicology. Tampere, Finland. Information: Congreszon
Ltd/ICT X, Itälahdenkatu 22 A, FIN-00210, Helsinki,
Finland, +358-9-5840-9350, fax: +358-9-5840-9555, 
e-mail: ictx2004@congreszon.fi, Internet: http://www.
ictx.org
11–16 July, Sun–Fri. Drug Metabolism. Plymouth, New
Hampshire. Information: Gordon Research Conferences,
PO Box 984, West Kingston, RI 02892-0984 USA, 
401-783-4011, fax: 401-783-7644, e-mail: grc@grcmail.
grc.uri.edu, Internet: http://www.grc.uri.edu
18–22 July, Sun–Thu. BioScience 2004–from Molecules to
Organisms. Glasgow, United Kingdom. Information:
Biochemical Society/Portland Press, 59 Portland
Place, London W1B 1QW UK, +44 (0) 20 7580 3481, fax:
+44 (0) 20 7637 7626, e-mail: meetings@BioScience2004.
org, Internet: http://www.bioscience2004.org/
18–23 July, Sun–Fri. Immunoglobulin Superfamily
Members In Infection, Immunity & Cancer. South
Hadley, Massachusetts. Information: Gordon Research
Conferences, PO Box 984, West Kingston, RI 02892-
0984 USA, 401-783-4011, fax: 401-783-7644, e-mail:
grc@grcmail.grc.uri.edu, Internet: http://www.grc.uri.edu
18–23 July, Sun–Fri. Microbial Toxins and Pathogenicity.
Andover, New Hampshire. Information: Gordon Research
Conferences, PO Box 984, West Kingston, RI 02892-
0984 USA, 401-783-4011, fax: 401-783-7644, e-mail:
grc@grcmail.grc.uri.edu, Internet: http://www.grc.uri.edu
August
1–4 August, Sun–Wed. Sixteenth Conference of the
International Society for Environmental Epidemiology.
New York, New York. Information: George D. Thurston,
Sc.D., e-mail: thurston@env.med.nyu.edu, Internet:
http://www.iseepi.org/
1–6 August, Thu–Tue. Cancer Models & Mechanisms.
Newport, Rhode Island. Information: Gordon Research
Conferences, PO Box 984, West Kingston, RI 02892-0984
USA, 401-783-4011, fax: 401-783-7644, e-mail: grc@
grc.org, Internet: http://www.grc.uri.edu
1–6 August, Thu–Tue. Industrial Ecology. Oxford, United
Kingdom. Information: Gordon Research Conferences, PO
Box 984, West Kingston, RI 02892-0984 USA, 401-783-
4011, fax: 401-783-7644, e-mail: grc@grc.org, Internet:
http://www.grc.uri.edu
3–7 August, Tue–Sat. The 12th International Conference
on Second Messengers and Phosphoproteins. Montréal,
Québec. Information: Events International Meeting
Planners Inc., 759 Square Victoria, Suite 300, Montréal,
QC H2Y 2J7 CANADA, 514-286-0855, fax: 514-286-
6066, Internet: http://www.secondmessengers2004.ca/
invitation.html
8–13 August, Sun–Fri. The Biology of Post-Transcriptional
Gene Regulation. Andover, New Hampshire. Information:
Gordon Research Conferences, PO Box 984, West
Kingston, RI 02892-0984 USA, 401-783-4011, fax: 401-
783-7644, e-mail: grc@grcmail.grc.uri.edu, Internet:
http://www.grc.uri.edu
14–18 August, Sat–Wed. The Protein Society’s 18th
Annual Symposium: Protein Structure, Function and
Disease. San Diego, California. Information: Cindy A.
Yablonski, The Protein Society, 9650 Rockville Pike,
Bethesda, MD 20814-3998 USA, 301-634-7277, fax:
301-634-7271, e-mail: cyablonski@proteinsociety.org,
Internet: http://www.faseb.org/protein/
22–27 August, Sun–Fri. 13th World Clean Air and
Environmental Protection Congress and Exhibition:
Environment at the Turning Point—The Interaction
of Climate Change and Pollution and their Impact
on Human Health, Natural Resources, and Social
Systems. London, United Kingdom. Information: Kenes
International, PO Box 56, Ben-Gurion Airport 70100,
Israel, +972 3 9727500, fax: +972 3 9727555, e-mail:
cleanair@kenes.com, Internet: http://www.kenes.com/
cleanair/
28 August–3 September, Sat–Fri. World Renewable Energy
Congress VII. Denver, Colorado. Information: Robert J.
Noun, Deputy Associate Director, External Relations,
National Renewable Energy Laboratory, 1617 Cole
Boulevard, MS 1623, Golden, CO 80401 USA, 303-275-
3062, fax: 303-275-3097, e-mail: bob_noun@nrel.gov,
Internet: http://www.nrel.gov/wrec/
29 August–1 September, Sun–Wed. 9th DCE/FECS
Conference on Chemistry and the Environment (DCE9) -
Behaviour of Chemicals in the Environment. Bordeaux,
France. Information: Sabrina Sartini, +33 5 40 00 29 26, 
e-mail: dce9@lptc.u-bordeaux1.fr, Internet: http://www.
lptc.u-bordeaux.fr/DCE9
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September
9–10 September, Thu–Fri. Persistent Contaminants: New
Priorities, New Concerns. Bear Mountain, New York.
Information: Hunter Blair, Mount Sinai School of
Medicine, Community & Preventive Medicine, Box 1057,
1 Gustave L. Levy Place, New York, NY 10029 USA, 212-
241-7905, fax: 212-423-9313, e-mail: hunter.blair@
mssm.edu, Internet: http://www-apps.niehs.nih.gov/sbrp/
Conf2000/Conf.cfm
12–17 September, Sun–Fri. Biology of Aging. Aussois,
France. Information: Gordon Research Conferences, PO
Box 984, West Kingston, RI 02892-0984 USA, 401-783-
4011, fax: 401-783-7644, e-mail: grc@grcmail.grc.uri.edu,
Internet: http://www.grc.uri.edu
19–23 September, Sun–Thu. First International
Symposium on Recent Advances in Environmental
Health Research. Jackson, Mississippi. Information:
Phyllis Martin, Center for Environmental Health,
Environmental Science Ph.D. Program, College of
Science, Engineering and Technology, Jackson State
University, 601-979-3473/601-979-3321, fax: 601-
979-2349, e-mail: Phyllis.Martin@jsums.edu
28 September–1 October, Tue–Fri. EORTC-NCI-AACR
International Conference on Molecular Targets and
Cancer Therapeutics. Geneva, Switzerland. Information:
EORTC-NCI-AACR 2004 Secretariat, FECS Conference
Unit, Avenue E. Mounier 83, 1200 Brussels, Belgium, +32
(2) 775 02 02, fax: +32 (2) 775 02 00, e-mail: ena2004@
fecs.be, Internet: http://www.fecs.be/Conferences/
ena2004/index.shtml
29–30 September, Wed–Thu. Persistent Contaminants:
New Priorities, New Concerns. Bear Mountain, New
York. Information: Hunter Blair, The Mount Sinai School
of Medicine, Community & Preventive Medicine, Box
1057, 1 Gustave L. Levy Place, New York, NY 10029 USA,
212-241-7905, fax: 212-423-9313, e-mail: hunter.blair@
mssm.edu, Internet: http://www-apps.niehs.nih.gov/sbrp/
conf/contaminants/index.html
October
3–5 October, Sun–Tue. 33rd Annual Meeting of the
American College of Clinical Pharmacology. Litchﬁeld
Park, Arizona. Information: American College of Clinical
Pharmacology, 3 Ellinwood Court, New Hartford, NY
13413 USA, 315-768-6117, fax: 315-768-6119, e-mail:
accp1ssu@aol.com, Internet: http://www.accp1.org/
3–6 October, Sun–Wed. The Endocrine Society’s Clinical
Endocrinology Update 2004. Baltimore, Maryland.
Information: A. Fassano & Company, PO Box 692, 44
Euclid Street, Woodbury, NJ 08096 USA, 856-251-0400,
fax: 856-251-0404, e-mail: exhibits@afassanoco.com,
Internet: http://www.afassanoco.com/ceu/
7–10 October, Thu–Sun. 3rd European Conference on
Pesticides and Related Organic Micropollutants in the
Environment. Halkidiki, Greece. Information: Zoi
Vamvetsou and Afroditi Sakellaridi (c/o T. Albanis),
University of Ioannina, Department of Chemistry,
Ioannina 45110, Greece, +30-2651-098348, 097177, fax:
+30-2651-097004, 098795, e-mail: talbanis@cc.uoi.gr
16–20 October, Sat–Wed. Third Annual Conference
on Frontiers in Cancer Prevention Research. Seattle,
Washington. Information: American Association for
Cancer Research, 615 Chestnut Street, 17th Floor,
Philadelphia, PA 19106-4404 USA, 215-440-9300, fax:
215-440-9313, e-mail: meetings@aacr.org, Internet:
http://www.aacr.org/4200m.asp
18–20 October, Mon–Wed. National Conference on the
Future of the Nation's Living Marine Resources.
Washington, DC. Information: Connie Barclay, 14th
Street & Constitution Avenue, NW, Room 6217,
Washington, DC 20230 USA, 301-713-2370, e-mail:
Connie.Barclay@noaa.gov, Internet: http://www.noaa.gov/
18–21 October, Mon–Thu. 20th Annual International
Conference on Soils, Sediments and Water. Amherst,
Massachusetts. Information: Denise Leonard, 413-545-
1239, e-mail: info@UMassSoils.com, Internet: http://
www.UMassSoils.com
24–27 October, Sun–Wed. Central and Eastern European
Environmental Health Conference: International Health
Sciences Solving Common Problems. Prague, Czech
Republic. Information: Nancy White, Texas A & M
University, 979-845-0203, e-mail: CEEHC04@cvm.
tamu.edu, Internet: http://tti.tamu.edu/conferences/ceehc/
25–29 October, Mon–Fri. Regional and Global
Perspectives on Haze: Causes, Consequences and
Controversies – Visibility Specialty Conference. Asheville,
North Carolina. Information: Air & Waste Management
Association, One Gateway Center, 3rd Floor, 420 Fort
Duquesne Boulevard, Pittsburgh, PA 15222-1435 USA,
412-232-3444, fax: 412-232-3450, e-mail: info@awma.org,
Internet: http://www.awma.org/ACE2004/
November
2–3 November, Tue–Wed. National Conference on
Health, Occupation, & Environment in Unorganized
Sector—Problems and Road Maps. Lucknow, India.
Information: Dr. S.K. Rastogi, Organizing Secretary,
NCHOE 2004, Deputy Director & Head Epidemiology
Section, Industrial Toxicology Research Centre, PO Box
80, MG Marg, Lucknow - 226 001 India, 0522-
2227586, 2213786 ext. 282, 283, fax: 0522-2228227,
2211547, e-mail: subhodhrastogi@yahoo.com, Internet:
http://www.itrcindia.org/nchoe/
7–10 November, Sun–Wed. Geological Society of
America—Annual Meeting and Exposition 2004.
Denver, Colorado. Information: Kevin Ricker, The
Geological Society of America, PO Box 9140, Boulder,
CO 80301-9140 USA, 303-357-1090, fax: 303-357-
1072, e-mail: meetings@geosociety.org, Internet:
http://www.geosociety.org/
7–11 November, Sun–Thu. AAPS Annual Meeting and
Exposition. Baltimore, Maryland. Information: American
Association of Pharmaceutical Scientists, 2107 Wilson
Boulevard, Suite 700, Arlington, VA 22201-3042 USA,
703-243-2800, fax: 703-243-9650, e-mail: aaps@aaps.org,
Internet: http://www.aaps.org/
8–9 November, Mon–Tue. LC/MS: Applications for Drug
Discovery and Development. San Diego, California.
Information: The Center for Business Intelligence Research,
Inc., 500 West Cummings Park, Suite 5400, Woburn, MA
01801 USA, 800-817-8601, fax: 781-939-2490, e-mail:
cbireg@cbinet.com, Internet: http://www.cbinet.com
December
10–11 December, Fri–Sat. World Foundation for Medical
Studies in Female Health - Annual Clinical Conference.
Chicago, Illinois. Information: World Foundation for
Medical Studies in Female Health, 405 Main Street, Port
Washington, NY 11050 USA, 516-944-3192, fax: 516-
944-8663, e-mail: mspinter@aol.com, Internet: http://
www.wffh.org/
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